Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY - FEDBIZOPPS ISSUE OF JANUARY 13, 2016 FBO #5164
MODIFICATION

B -- Database Development and Management Services for the Division of Parasitic Diseases and Malaria

Notice Date
1/11/2016
 
Notice Type
Modification/Amendment
 
NAICS
541990 — All Other Professional, Scientific, and Technical Services
 
Contracting Office
Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
 
ZIP Code
30341-4146
 
Solicitation Number
2016-N-17718
 
Archive Date
2/6/2016
 
Point of Contact
Linda F. Williams, Phone: 770-488-2692
 
E-Mail Address
luw9@cdc.gov
(luw9@cdc.gov)
 
Small Business Set-Aside
N/A
 
Description
The Centers for Disease Control and Prevention (CDC), Center for Global Health (CGH), Division of Parasitic Diseases and Malaria (DPDM), intends to negotiate a sole source contract with EMMES, 401 N. Washington St., Suite 700, Rockville, MD 20850, to provide clinical trial data management services that meet the regulatory and reporting requirements for the following vaccine clinical trial: Safety, Tolerability and Efficacy of PfSPZ Vaccine Administered by Direct Venous Inoculation (DVI) to Healthy Children and Infants 5 Months through 12 Years of Age Living in an Area of High Malaria Transmission in Western Kenya: Age De-escalation and Dose Escalation and a Double Blind, Randomized Placebo-Controlled Trial for Safety and Efficacy. Emmes has experience with PfSPZ malaria vaccine trials and data management in Africa. The efficacy of a malaria vaccine may be related to transmission levels, prior malaria exposure and acquired immunity, and other factors particular to where the vaccine is tested. It is essential that CDC objectively and accurately assesses the performance of the PfSPZ vaccine and compare the performance across multiple malaria transmission levels, populations, countries and age groups. Such comparisons are frequently very complex because of different methods in collecting data, different measures of efficacy, and the use of different analyses. The design of data collection tools, data management and monitoring, and analysis for the majority of the PfSPZ studies done or planned were or will be managed by Emmes. To ensure coordination and comparability, we are requesting sole source contracting of Emmes, so they can provide similar data management services for the trial we are planning, so that a seamless comparison of data can occur between sites. Due to the collaborative nature of this initiative, it is expected that utilization of existing systems, processes, and technical expertise will be the most efficient approach to achieving project objectives. Establishment of data management continuity of support will greatly reduce delays in addressing this urgent global research need. The use of developed processes and existing systems will ensure the results generated from the proposed clinical trial in Kenya can be rapidly and efficiently analyzed upon study completion, and would expedite quick and efficient harmonization, merging, and integration of data from this study with previous/subsequent studies in order to generate the appropriate information needed to inform immunological assessment, safety, and clinical efficacy. The use of other than full and open competition for this acquisition is conducted under the authority of 41 United States Code (U.S.C.) 253(c)(1) as set forth in Federal Acquisition Regulations, Subpart 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements. This notice of intent is not a request for competitive proposals. A determination to compete this procurement based on a response to this notice is solely within the discretion of the Government. Interested parties who believe they possess the capabilities to satisfy this requirement should submit a Capability Statement demonstrating their abilities to meet this requirement. All responses will be considered. All Capability Statements shall be received by the closing date of this synopsis and shall be submitted in writing. Responses may be sent via email to luw9@cdc.gov. No solicitation will be issued. No telephone inquiries will be accepted.
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2016-N-17718/listing.html)
 
Place of Performance
Address: Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Georgia, 30341-3724, United States
Zip Code: 30341-3724
 
Record
SN03988115-W 20160113/160111234535-c50ade47a7c4655fb573266b6e241538 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.